Cited by 712Protein Kinase Regulation and GTPase SignalingProtein Tyrosine PhosphatasesCellular transport and secretion

The DOI matches its Crossref record; 328 of the 329 references it cites were found in a registry or an index.

Ras history: The saga continues

Open access

Cox, Adrienne D., Der, Channing J.·2010·Small GTPases

DOI 10.4161/sgtp.1.1.12178PMC PMC3109476

Open this paper in CoChat — free account Open PDF

Abstract

Although the roots of Ras sprouted from the rich history of retrovirus research, it was the discovery of mutationally activated RAS genes in human cancer in 1982 that stimulated an intensive research effort to understand Ras protein structure, biochemistry and biology. While the ultimate goal has been developing anti-Ras drugs for cancer treatment, discoveries from Ras have laid the foundation for three broad areas of science. First, they focused studies on the origins of cancer to the molecular level, with the subsequent discovery of genes mutated in cancer that now number in the thousands. Second, elucidation of the biochemical mechanisms by which Ras facilitates signal transduction established many of our fundamental concepts of how a normal cell orchestrates responses to extracellular cues. Third, Ras proteins are also founding members of a large superfamily of small GTPases that regulate all key cellular processes and established the versatile role of small GTP-binding proteins in biology. We highlight some of the key findings of the last 28 years.

Integrity signals

Registry

Crossref · 10.4161/sgtp.1.1.12178

Cites

328 of 328 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cancer statistics, 2009
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Rab GTPases as coordinators of vesicle traffic
Stenmark, H. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2728 · Cited by 3,413
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Show all 329 references

Research works printed but not linked: 7

Lundquist EA. Small GTPases. WormBook 2006; 1 - 18
10.1128/mcb.11.5.2641-2646.1991 · DOI
10.1128/mcb.14.11.7483-7491.1994 · DOI · Paper page
10.1101/gad.993902 · DOI
10.1128/mcb.6.1.116-122.1986 · DOI
10.1042/bj3610243 · DOI
Stevens EV, Der CJ. Van Golen K. Rho History. The Rho GTPases in Cancer 2010; Springer

Sorted by citations

Items 101–200 of 712

Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9
Yu, B., Swatkoski, S., Holly, A. J., Lee, L. C., Giroux, V., Lee, C.-S., Hsu, D. J., Smith, J. L., Yuen, G., Yue, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415569112 · Cited by 76
RASopathies: From germline mutations to somatic and multigenic diseases
Riller, Q., & Rieux‐Laucat, F. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.06.004 · Cited by 83
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75
Metabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 76
Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
Strand, M. S., Krasnick, B. A., Pan, H., Zhang, X., Bi, Y., Brooks, C., Wetzel, C., Sankpal, N., Fleming, T., Goedegebuure, S. P., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27109 · Cited by 74
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 75
A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation
Simanshu, D. K., & Morrison, D. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1494 · Cited by 70
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
Arl13b regulates Shh signaling from both inside and outside the cilium
Mariani, L. E., Bijlsma, M. F., Ivanova, A., Suciu, S. K., Kahn, R., & Caspary, T. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-03-0189 · Cited by 76
PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 79
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 71
Self-citation
Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain
Antic, I., Biancucci, M., Zhu, Y., Gius, D. R., & Satchell, K. J. F. (2015) · Nature Communications · doi:10.1038/ncomms8396 · Cited by 72
The RalB Small GTPase Mediates Formation of Invadopodia through a GTPase-Activating Protein-Independent Function of the RalBP1/RLIP76 Effector
Neel, N. F., Rossman, K. L., Martin, T. D., Hayes, T. K., Yeh, J. J., & Der, C. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06291-11 · Cited by 71
Self-citation
Ras and exosome signaling
Sexton, R. E., Mpilla, G., Kim, S. H., Philip, P. A., & Azmi, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.004 · Cited by 71
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 74
Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis
Prakash, P., Hancock, J. F., & Gorfe, A. A. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24786 · Cited by 69
Evolution of the Ras-like small GTPases and their regulators
van Dam, T. J. P., Bos, J. L., & Snel, ‎. (2011) · Small GTPases · doi:10.4161/sgtp.2.1.15113 · Cited by 70
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer
Bartolini, A., Cardaci, S., Lamba, S., Oddo, D., Marchiò, C., Cassoni, P., Amoreo, C. A., Corti, G., Testori, A., Bussolino, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2664 · Cited by 68
Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
Luo, L., Li, Y., Liu, Z., Fan, X., Duan, F., Li, R., Yao, X., Leung, E. L., & Liu, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00199 · Cited by 69
Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression
Gao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2020) · Theranostics · doi:10.7150/thno.42325 · Cited by 72
The Significance of Ras Activity in Pancreatic Cancer Initiation
Logsdon, C. D., & Lu, W. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15020 · Cited by 68
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
Cregg, J., Pota, K., Tomlinson, A. C. A., Yano, J. K., Marquez, A., Liu, Y., Schulze, C. J., Seamon, K. J., Holderfield, M. T., Wei, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02313 · Cited by 69
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
H-Ras transfers from B to T cells via tunneling nanotubes
Rainy, N., Chetrit, D., Rouger, V., Vernitsky, H., Rechavi, O., Marguet, D., Goldstein, I., Ehrlich, M., & Kloog, Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.245 · Cited by 67
KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis
Du, L., Kim, J. J., Shen, J., Chen, B., & Dai, N. (2017) · Oncotarget · doi:10.18632/oncotarget.14549 · Cited by 71
An engineered protein antagonist of K-Ras/B-Raf interaction
Kauke, M. J., Traxlmayr, M. W., Parker, J. A., Kiefer, J. D., Knihtila, R., McGee, J., Verdine, G., Mattos, C., & Wittrup, K. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05889-7 · Cited by 64
Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System
Röth, S., Macartney, T., Konopacka, A., Chan, K.-H., Zhou, H., Queisser, M. A., & Sapkota, G. P. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.06.012 · Cited by 67
Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs
Prakash, P., Litwin, D. B., Hong, L., Sarkar‐Banerjee, S., Dolino, D. M., Zhou, Y., Hancock, J. F., Jayaraman, V., & Gorfe, A. A. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.12.011 · Cited by 62
Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1
Evelyn, C. R., Duan, X., Biesiada, J., Seibel, W. L., Meller, J., & Zheng, Y. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.018 · Cited by 63
K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function
Cao, S., Chung, S., Kim, S., Li, Z., Manor, D., & Buck, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004021 · Cited by 63
“Pathway drug cocktail”: targeting Ras signaling based on structural pathways
Nussinov, R., Tsai, C.-J., & Mattos, C. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.07.009 · Cited by 62
Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer
Tripathi, K., & Garg, M. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0441-3 · Cited by 62
Activated Rho GTPases in Cancer—The Beginning of a New Paradigm
Aspenström, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123949 · Cited by 61
Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 62
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma
Windon, A. L., Loaiza‐Bonilla, A., Jensen, C. E., Randall, M. P., Morrissette, J. J. D., & Shroff, S. G. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.10.14 · Cited by 61
Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)
Garcia, J., Forestier, J., Dusserre, E., Wozny, A., Geiguer, F., Merle, P., Tissot, C., Ferraro‐Peyret, C., Jones, F. S., Edelstein, D. L., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24950 · Cited by 61
Biomarkers and Targeted Therapy in Pancreatic Cancer
Karandish, F., & Mallik, S. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s34414 · Cited by 82
Endothelial Rap1 (Ras-Association Proximate 1) Restricts Inflammatory Signaling to Protect From the Progression of Atherosclerosis
Singh, B., Kosuru, R., Lakshmikanthan, S., Sorci‐Thomas, M. G., Zhang, D. X., Sparapani, R., Vasquez-Vivar, J. M., & Chrzanowska‐Wodnicka, M. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315401 · Cited by 60
Universal Method for Protein Immobilization on Chemically Functionalized Germanium Investigated by ATR-FTIR Difference Spectroscopy
Schartner, J., Güldenhaupt, J., Mei, B. T., Rögner, M., Muhler, M., Gerwert, K. B., & Kötting, C. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400253p · Cited by 60
Hydrolysis of Guanosine Triphosphate (GTP) by the Ras·GAP Protein Complex: Reaction Mechanism and Kinetic Scheme
Khrenova, M. G., Grigorenko, B. L., Kolomeisky, A. B., & Nemukhin, A. V. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b07238 · Cited by 60
Therapeutic Potential of Targeting PAK Signaling
Senapedis, W. T., Crochiere, M. L., Baloglu, E., & Landesman, Y. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150617111414 · Cited by 59
The clinical relevance of KRAS gene mutation in non-small-cell lung cancer
Tı́már, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000051 · Cited by 62
Codon usage regulates human KRAS expression at both transcriptional and translational levels
Fu, J., Dang, Y., Counter, C. M., & Liu, Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004908 · Cited by 60
The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis
Cazzanelli, G., Pereira, F. D. S., Alves, S., Francisco, R., Azevedo, L., Carvalho, P. D., Almeida, A. F., Côrte‐Real, M., Oliveira, M. J., Lucas, C., et al. (2018) · Cells · doi:10.3390/cells7020014 · Cited by 60
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng, H., Zhang, Y., Bos, P. H., Chambers, J. M., Dupont, M. M., & Stockwell, B. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01300 · Cited by 56
Advancing RAS/RASopathy therapies: An NCI‐sponsored intramural and extramural collaboration for the study of RASopathies
Gross, A. M., Frone, M. N., Gripp, K. W., Gelb, B. D., Schoyer, L., Schill, L., Stronach, B. E., Biesecker, L. G., Esposito, D., Hernandez, E. R., et al. (2020) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61485 · Cited by 57
Dock GEFs and their therapeutic potential: Neuroprotection and axon regeneration
Namekata, K., Kimura, A., Kawamura, K., Harada, C., & Harada, T. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.06.005 · Cited by 57
High-throughput, single-particle tracking reveals nested membrane domains that dictate KRasG12D diffusion and trafficking
Lee, Y., Phelps, C. E., Huang, T., Mostofian, B., Wu, L., Zhang, Y., Tao, K. X., Chang, Y. H., Stork, P. A., Gray, J. W., et al. (2019) · eLife · doi:10.7554/elife.46393 · Cited by 56
Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma
Heakal, Y., KESTER, M. A., & Savage, S. W. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q363 · Cited by 55
MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
Moghbeli, M. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00882-1 · Cited by 58
Conformational SERS Classification of K‐Ras Point Mutations for Cancer Diagnostics
Morlà‐Folch, J., Gisbert‐Quilis, P., Masetti, M., García‐Rico, E., Álvarez‐Puebla, R. A., & Guerrini, L. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611243 · Cited by 55
Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Khan, I., Spencer-Smith, R., & O’Bryan, J. P. (2019) · Oncogene · doi:10.1038/s41388-018-0636-y · Cited by 54
Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants: Interaction Patterns in Ras Oncogenic Mutants
Sayyed-Ahmad, A., Prakash, P., & Gorfe, A. A. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25317 · Cited by 54
K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 56
Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity
Leung, E. L., Luo, L. X., Liu, Z. Q., Wong, V. K. W., Lu, L., Xie, Y., Zhang, N., Qu, Y. Q., Fan, X., Li, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0065-9 · Cited by 58
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer
Gagliardi, M. E., Pitner, M. K., Park, J., Xie, X., Saso, H., Larson, R. A., Sammons, R. M., Chen, H., Wei, C., Masuda, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65250-3 · Cited by 54
Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
Lee, W., Lee, J. H., Jun, S., Lee, J. H., & Bang, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30205-2 · Cited by 53
Post-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 54
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0296 · Cited by 53
Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers
Baker, N. M., Chow, H. Y., Chernoff, J., & Der, C. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1727 · Cited by 52
Self-citation
The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy
Malaney, P., Uversky, V. N., & Davé, V. (2013) · Molecular BioSystems · doi:10.1039/c3mb70267g · Cited by 50
Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms
Longo, J. F., Weber, S. M., Turner-Ivey, B., & Carroll, S. L. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000197 · Cited by 52
Probing the Conformational and Energy Landscapes of KRAS Membrane Orientation
Prakash, P., & Gorfe, A. A. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b05796 · Cited by 51
Lessons from computer simulations of Ras proteins in solution and in membrane
Prakash, P., & Gorfe, A. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.07.024 · Cited by 49
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 52
κB-Ras Proteins Regulate Both NF-κB-Dependent Inflammation and Ral-Dependent Proliferation
Oeckinghaus, A., Postler, T. S., Rao, P., Schmitt, H., Schmitt, V., Grinberg‐Bleyer, Y., Kühn, L. I., Gruber, C. W., Lienhard, G. E., & Ghosh, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.015 · Cited by 51
Essential Role of Cdc42 in Ras-Induced Transformation Revealed by Gene Targeting
Stengel, K. R., & Zheng, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037317 · Cited by 51
Drug for an 'undruggable' protein
Baker, N. M., & Der, C. J. (2013) · Nature · doi:10.1038/nature12248 · Cited by 49
Self-citation
DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers
Wang, D., Qian, X., Rajaram, M., Durkin, M. E., & Lowy, D. R. (2016) · Oncotarget · doi:10.18632/oncotarget.9266 · Cited by 50
Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release
Garant, K. A., Shmulevitz, M., Pan, L., Daigle, R., Ahn, D.-G., Gujar, S. A., & Lee, P. W. K. (2015) · Oncogene · doi:10.1038/onc.2015.136 · Cited by 47
Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 49
Membrane orientation dynamics of lipid-modified small GTPases
Prakash, P., & Gorfe, A. A. (2016) · Small GTPases · doi:10.1080/21541248.2016.1211067 · Cited by 48
Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT OncogenesPreprint
Parsons, R. E. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036129 · Cited by 48
Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma
Kulkarni, P., Leite, V. B. P., Roy, S., Bhattacharyya, S., Mohanty, A. R., Achuthan, S., Singh, D., Appadurai, R., Govindan Rangarajan, C., Weninger, K., et al. (2022) · Biophysics Reviews · doi:10.1063/5.0080512 · Cited by 49
MEK inhibitors in oncology: a patent review (2015-Present)
Mahapatra, D. K., Asati, V., & Bharti, S. K. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1339688 · Cited by 47
Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts
Marshall, C. B., Meiri, D., Smith, M. J., Mazhab-Jafari, M. T., Gasmi-Seabrook, G. M. C., Rottapel, R., Stambolic, V., & Ikura, M. (2012) · Methods · doi:10.1016/j.ymeth.2012.06.014 · Cited by 46
KRAS Engages AGO2 to Enhance Cellular Transformation
Shankar, S., Pitchiaya, S., Malik, R., Kothari, V., Hosono, Y., Yocum, A. K., Gundlapalli, H., White, Y. N., Firestone, A. J., Cao, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.034 · Cited by 46
Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Ma, B., & Nussinov, R. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990073 · Cited by 45
Targeting mutated GTPase KRAS in tumor therapies
Fan, G., Lou, L., Song, Z., Zhang, X., & Xiong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113816 · Cited by 46
The role of KRAS splice variants in cancer biology
Nuevo‐Tapioles, C., & Philips, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1033348 · Cited by 48
Conformational and Dynamical Effects of Tyr32 Phosphorylation in K-Ras: Molecular Dynamics Simulation and Markov State Models Analysis
Khaled, M., Gorfe, A. A., & Sayyed–Ahmad, A. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b05768 · Cited by 45
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Zhang, S. S., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s334623 · Cited by 44
RASAL3, a novel hematopoietic RasGAP protein, regulates the number and functions of NKT cells
Saito, S., Kawamura, T., Higuchi, M., Kobayashi, T., Yoshita‐Takahashi, M., Yamazaki, M., Abe, M., Sakimura, K., Kanda, Y., Kawamura, H., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201444977 · Cited by 44
DRoP: A Water Analysis Program Identifies Ras-GTP-Specific Pathway of Communication between Membrane-Interacting Regions and the Active Site
Kearney, B. M., Johnson, C. W., Roberts, D. M., Swartz, P., & Mattos, C. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.10.036 · Cited by 43
FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice
Goldberg, L., Israeli, R., & Kloog, Y. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.24 · Cited by 44
Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway
Zhao, J., & Luo, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095158 · Cited by 43
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M. R., Greenstein, A. E., & Townsend, J. P. (2018) · Oncogene · doi:10.1038/s41388-017-0105-z · Cited by 43
Multi‐target, ensemble‐based virtual screening yields novel allosteric KRAS inhibitors at high success rate
Gupta, A. K., Wang, X., Pagba, C. V., Prakash, P., Sarkar‐Banerjee, S., Putkey, J. A., & Gorfe, A. A. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13519 · Cited by 43
Comprehensive TCM molecular networking based on MS/MS in silico spectra with integration of virtual screening and affinity MS screening for discovering functional ligands from natural herbs
Wang, Z., Kim, U., Liu, J., Cheng, C., Wu, W., Guo, S., Feng, Y., Quinn, R. J., Hou, Y., & Bai, G. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01962-4 · Cited by 42
In-silico design of peptide inhibitors of K-Ras target in cancer disease
Ghufran, M., Rehman, A. U., Shah, M., Ayaz, M., Ng, H. L., & Wadood, A. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704880 · Cited by 42
DA-Raf-Mediated Suppression of the Ras—ERK Pathway Is Essential for TGF-β1-Induced Epithelial—Mesenchymal Transition in Alveolar Epithelial Type 2 Cells
Watanabe‐Takano, H., Takano, K., Hatano, M., Tokuhisa, T., & Endo, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127888 · Cited by 42
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth
Cook, D. R., Kang, M. S., Martin, T. D., Galanko, J. A., Loeza, G. H., Trembath, D. G., Justilien, V., Pickering, K. A., Vincent, D. F., Jarosch, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4218 · Cited by 41
Self-citation
RHOA takes the RHOad less traveled to cancer
Schaefer, A., & Der, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.005 · Cited by 41
Self-citation
The Small G Protein H-Ras in the Mesolimbic System Is a Molecular Gateway to Alcohol-Seeking and Excessive Drinking Behaviors
Hamida, S. B., Neasta, J., Lasek, A. W., Kharazia, V., Zou, M. E., Carnicella, S., Janak, P. H., & Dorit Ron, A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2846-12.2012 · Cited by 39
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Araujo, L. H., Souza, B. M., Leite, L. R., Parma, S. A. F., Lopes, N. P., Malta, F. S. V., & Freire, M. C. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-07884-8 · Cited by 41
Structural insights into the small G-protein Arl13B and implications for Joubert syndrome
Miertzschke, M., Koerner, C., Spoerner, M., & Wittinghofer, A. (2013) · Biochemical Journal · doi:10.1042/bj20131097 · Cited by 40
Neutron Crystal Structure of RAS GTPase Puts in Question the Protonation State of the GTP γ-Phosphate
Knihtila, R., Holzapfel, G. A., Weiss, K. L., Meilleur, F., & Mattos, C. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679860 · Cited by 39
Impairment of K‐Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR‐143
Akao, Y., Kumazaki, M., Shinohara, H., Sugito, N., Kuranaga, Y., Tsujino, T., Yoshikawa, Y., & Kitade, Y. (2018) · Cancer Science · doi:10.1111/cas.13559 · Cited by 40
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vidimar, V., Beilhartz, G. L., Park, M., Biancucci, M., Kieffer, M. B., Gius, D. R., Melnyk, R. A., & Satchell, K. J. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000312117 · Cited by 39
Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties
Whitley, M. J., Tran, T. H., Rigby, M., Yi, M., Dharmaiah, S., Waybright, T. J., Ramakrishnan, N., Perkins, S. C., Taylor, T. E., Messing, S. A. J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj4137 · Cited by 42

Authors: Cox, A. D., & Der, C. J.
Affiliations: University of North Carolina at Chapel Hill (US)
ORCID: Cox, Adrienne D.
Der, Channing J.
Venue: Small GTPases
Publisher: Informa UK Limited
Published: 2010-07
Volume: 1
Issue: 1
Pages: 2-27
ISSN: 2154-1248 (ISSN-L)
2154-1256
DOI: 10.4161/sgtp.1.1.12178
PMC: PMC3109476
OpenAlex: W2333950962
Cited by: 706
References: 329
Citations by year: 2026: 19 · 2025: 39 · 2024: 48 · 2023: 43 · 2022: 78 · 2021: 59 · 2020: 71 · 2019: 70 · 2018: 43 · 2017: 40 · 2016: 44 · 2015: 49 · 2014: 30 · 2013: 34 · 2012: 21
FWCI: 9.37
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Small GTPases (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca042978-30)
National Cancer Institute (R01CA109550, R01-CA042978, P50CA106991, U19CA067771, R01CA127152)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords: Ras, ras gene, oncogenic mutations, tumor origin, signal transduction, G proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ras history: The saga continues

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks